YUNNAN BAIYAO GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.12 CNY | -0.46% |
|
-1.60% | +10.11% |
| May. 13 | Yunnan Baiyao's Unit to Conduct Clinical Trials on Prostate Cancer Drug | MT |
| May. 13 | Yunnan Baiyao to Conduct Clinical Trials on Flurbiprofen Gel Patch | MT |
ETFs positioned on Yunnan Baiyao Group Co.,Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 17 M€ | +2.99% | - | |
| 0.00% | 105 M€ | +3.68% | - | |
| 0.00% | 15 M€ | +17.77% | ||
| 0.00% | 54 M€ | +0.64% | - | |
| 0.00% | 8 M€ | +0.90% | - |
Yunnan Baiyao Group Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical products. The group proposes primarily traditional medicine products, phytobiological products, body care products, antibiotics and anti-inflammatory.
China accounts for 98.9% of net sales.
Sector
Pharmaceuticals
Calendar
2024-06-10
- Extraordinary Shareholders Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
54.12
CNY
Average target price
64.08
CNY
Spread / Average Target
+18.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.11% | 13.39B | |
| +37.46% | 727B | |
| -7.90% | 354B | |
| +15.58% | 328B | |
| -0.51% | 277B | |
| +13.47% | 243B | |
| +7.35% | 205B | |
| -6.42% | 203B | |
| +3.82% | 164B | |
| -1.98% | 164B |
- Stock Market
- Equities
- 000538 Stock
- Funds and ETFs Yunnan Baiyao Group Co.,Ltd
